Other novel rhGAA delivery approaches have been evaluated for safety and efficacy, including VAL-1221 (Valerion Therapeutics) which is a fusion protein of monoclonal lupus anti DNA-antibody 3E10 with rhGAA, allowing the modified rhGAA to enter the cell via the equilibrative nucleoside transporter 2 (ENT2), independent of the CI-M6PR. Here, SLC29A2 is linked to systemic lupus erythematosus.